ORALE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ADIPÖSEN, NICHT DIABETISCHEN SÄUGETIEREN, EINSCHLIESSLICH MENSCHEN

Oral pharmaceutical compositions comprising an effective amount of a tungsten (VI) compound, preferably of a tungstate salt, and more preferably of sodium tungstate (Na2WO4), are useful to fight obesity/overweight in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate...

Full description

Saved in:
Bibliographic Details
Main Authors FERNANDEZ ALVAREZ, JOSEFA, GUINOVART CIRERA, JOAN-JOSEP, CLARET CARLES, MARC, GOMIS DE BARBARA, RAMON
Format Patent
LanguageGerman
Published 15.11.2006
Edition7
Online AccessGet full text

Cover

More Information
Summary:Oral pharmaceutical compositions comprising an effective amount of a tungsten (VI) compound, preferably of a tungstate salt, and more preferably of sodium tungstate (Na2WO4), are useful to fight obesity/overweight in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in a model of rat diet-induced obesity called "cafeteria diet" has been assessed. These obese rats are a good model of non-diabetic obese mammals, including humans. The prophylactic, therapeutic and/or cosmetic treatment of obesity that derives from this invention is surprising and, over treatments previously proposed in the art, involves advantages such as efficacy, lack of toxicity, and relatively low price. Therefore, the oral compositions of the present invention are useful for oral treatment of obesity/overweight in non-diabetic mammals, including humans.
Bibliography:Application Number: AT20020732763T